arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

Bausch Health Companies Inc.

BHC
$7.97 ▼ -0.37 (-4.44%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
73 Visible periods
33 Metrics
Peer-ranked Benchmarks
Price Chart
57
Health
Fair
Moderately Bearish
auto_awesome

Analytical Summary

Bausch Health Companies Inc. faces fundamental challenges with weakness in Return on Common Equity (%). Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $3.0B
Dividend Yield —
Revenue Growth 9.7% ↘
Op. Margin 33.4% ↗
ROIC 3.8% ↗
FCF / Share $1.99 ↗
Trailing P/E 6.9x
Price / Book —
FCF Yield 25.0%
Debt / Equity -15.54
info Valuation on last close. End-of-day price, Nov 5, 2026.

73-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$2.94B
↑ +9.7% —
Net Income Profit after all expenses
$436.00M
↑ +143.6% —
Operating Margin Operating profit as % of sales
33.4%
↑ +28.8% 72th
FCF / Share Free cash flow per share
$1.99
↑ +26.0% —
Long-Term Debt Long-term obligations
$20.64B
↓ -0.5% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability →
56
Returns ↑
24
Financial Health ↑
78
Cash Quality
96

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 19 years · 73 quarters